Literature DB >> 20980263

X-ray and biochemical analysis of N370S mutant human acid β-glucosidase.

Ronnie R Wei1, Heather Hughes, Susan Boucher, Julie J Bird, Nicholas Guziewicz, Scott M Van Patten, Huawei Qiu, Clark Qun Pan, Tim Edmunds.   

Abstract

Gaucher disease is caused by mutations in the enzyme acid β-glucosidase (GCase), the most common of which is the substitution of serine for asparagine at residue 370 (N370S). To characterize the nature of this mutation, we expressed human N370S GCase in insect cells and compared the x-ray structure and biochemical properties of the purified protein with that of the recombinant human GCase (imiglucerase, Cerezyme®). The x-ray structure of N370S mutant acid β-glucosidase at acidic and neutral pH values indicates that the overall folding of the N370S mutant is identical to that of recombinant GCase. Subtle differences were observed in the conformation of a flexible loop at the active site and in the hydrogen bonding ability of aromatic residues on this loop with residue 370 and the catalytic residues Glu-235 and Glu-340. Circular dichroism spectroscopy showed a pH-dependent change in the environment of tryptophan residues in imiglucerase that is absent in N370S GCase. The mutant protein was catalytically deficient with reduced V(max) and increased K(m) values for the substrate p-nitrophenyl-β-D-glucopyranoside and reduced sensitivity to competitive inhibitors. N370S GCase was more stable to thermal denaturation and had an increased lysosomal half-life compared with imiglucerase following uptake into macrophages. The competitive inhibitor N-(n-nonyl)deoxynojirimycin increased lysosomal levels of both N370S and imiglucerase 2-3-fold by reducing lysosomal degradation. Overall, these data indicate that the N370S mutation results in a normally folded but less flexible protein with reduced catalytic activity compared with imiglucerase.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20980263      PMCID: PMC3012987          DOI: 10.1074/jbc.M110.150433

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model.

Authors:  A A Vaguine; J Richelle; S J Wodak
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-01-01

Review 2.  Hematologically important mutations: Gaucher disease.

Authors:  Ernest Beutler; Terri Gelbart; C Ronald Scott
Journal:  Blood Cells Mol Dis       Date:  2005-09-26       Impact factor: 3.039

3.  Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.

Authors:  Raquel L Lieberman; Brandon A Wustman; Pedro Huertas; Allan C Powe; Corey W Pine; Richie Khanna; Michael G Schlossmacher; Dagmar Ringe; Gregory A Petsko
Journal:  Nat Chem Biol       Date:  2006-12-24       Impact factor: 15.040

4.  The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms.

Authors:  Richard A Steet; Stephen Chung; Brandon Wustman; Allan Powe; Hung Do; Stuart A Kornfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-31       Impact factor: 11.205

5.  Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutations.

Authors:  Benjamin Liou; Andrzej Kazimierczuk; Min Zhang; C Ronald Scott; Rashmi S Hegde; Gregory A Grabowski
Journal:  J Biol Chem       Date:  2005-11-17       Impact factor: 5.157

6.  Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease.

Authors:  R O Brady; J N Kanfer; R M Bradley; D Shapiro
Journal:  J Clin Invest       Date:  1966-07       Impact factor: 14.808

7.  Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression.

Authors:  M E Grace; K M Newman; V Scheinker; A Berg-Fussman; G A Grabowski
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

8.  Characterization of human glucocerebrosidase from different mutant alleles.

Authors:  T Ohashi; C M Hong; S Weiler; J M Tomich; J M Aerts; J M Tager; J A Barranger
Journal:  J Biol Chem       Date:  1991-02-25       Impact factor: 5.157

9.  Characterization of the activation of rat liver beta-glucosidase by sialosylgangliotetraosylceramide.

Authors:  A Basu; R H Glew
Journal:  J Biol Chem       Date:  1985-10-25       Impact factor: 5.157

Review 10.  Scaling and assessment of data quality.

Authors:  Philip Evans
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-12-14
View more
  27 in total

1.  Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.

Authors:  Ying Sun; Benjamin Liou; You-Hai Xu; Brian Quinn; Wujuan Zhang; Rick Hamler; Kenneth D R Setchell; Gregory A Grabowski
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

2.  Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease.

Authors:  Susan D Orwig; Yun Lei Tan; Neil P Grimster; Zhanqian Yu; Evan T Powers; Jeffery W Kelly; Raquel L Lieberman
Journal:  Biochemistry       Date:  2011-11-14       Impact factor: 3.162

3.  Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase.

Authors:  Samarjit Patnaik; Wei Zheng; Jae H Choi; Omid Motabar; Noel Southall; Wendy Westbroek; Wendy A Lea; Arash Velayati; Ehud Goldin; Ellen Sidransky; William Leister; Juan J Marugan
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

4.  Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant.

Authors:  Gholamreza Babajani; Michael B Tropak; Don J Mahuran; Allison R Kermode
Journal:  Mol Genet Metab       Date:  2012-04-26       Impact factor: 4.797

Review 5.  Minireview: applied structural bioinformatics in proteomics.

Authors:  Yee Siew Choong; Gee Jun Tye; Theam Soon Lim
Journal:  Protein J       Date:  2013-10       Impact factor: 2.371

Review 6.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

7.  Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease.

Authors:  Ethan D Goddard-Borger; Michael B Tropak; Sayuri Yonekawa; Christina Tysoe; Don J Mahuran; Stephen G Withers
Journal:  J Med Chem       Date:  2012-03-06       Impact factor: 7.446

8.  Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.

Authors:  Thai Leong Yap; James M Gruschus; Arash Velayati; Wendy Westbroek; Ehud Goldin; Nima Moaven; Ellen Sidransky; Jennifer C Lee
Journal:  J Biol Chem       Date:  2011-06-08       Impact factor: 5.157

9.  Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses.

Authors:  Fredj Ben Bdira; Marta Artola; Herman S Overkleeft; Marcellus Ubbink; Johannes M F G Aerts
Journal:  J Lipid Res       Date:  2018-10-02       Impact factor: 5.922

10.  Structural snapshots illustrate the catalytic cycle of β-galactocerebrosidase, the defective enzyme in Krabbe disease.

Authors:  Chris H Hill; Stephen C Graham; Randy J Read; Janet E Deane
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.